Any honeymoon expected for Brent Saunders at Bausch + Lomb, Corporation may or may not be over after a year at the helm, but the special period known as market exclusivity the firm’s Lumify OTC switch eye drops enjoyed in the US could be passing with the first generic copy approved.
The brimonidine tartrate 0.025% ophthalmic solution indicated for relief of redness remains a key sales driver among the Canadian firm’s...